GRF-P Fair Value & Analysis
Other · ES · Market cap €7.8B
Fair value as of: Jul 1, 2026
From 24 valuation models · updated 21 days ago
Fair value updated Jul 1, 2026, revised from €3.06 to €3.78 (+23.5%) since Jun 24, 2026. Share price +0.5% over the past month.
Price vs Fair Value (12 months)
12‑month range €6.18 – €9.57 · fair‑value band €3.58 – €7.14 · the €6.67 price screens above the €3.78 fair value. As of Jul 1, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
GRF-P (GRF-P) currently trades at €6.67, while our model-based Fair Value estimate is €3.78, implying the stock looks roughly 43.3% overvalued today. We read business quality at 49/100 (below-average quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Net debt stands at €7.7B. Fundamentals as of Jul 1, 2026
Our scenario range runs from €3.58 (bear case) to €7.14 (bull case); at €6.67, the current price sits within that range. The share trades about 30% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Other peers we cover trades at -16% fair-value upside, at -43%, GRF-P screens richer than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 1, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
GRF-P reported revenue of €7.5B in FY2025 versus €4.9B in FY2021, a compound +11.1%/yr. Reported net income was €402M in FY2025, compounding +20.8%/yr from FY2021.
Is GRF-P fairly valued? → Check now
Recent news
- European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading
- Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
- European Equities Traded in the US as American Depositary Receipts Advance Wednesday
- Grifols (GRFS) Launches FESILTY in the U.S. for Congenital Fibrinogen Deficiency Treatment
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 1, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €269.92 | -48% |
| Sony Corporation SON1 | €17.58 | €37.56 | +114% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $64.93 | +286% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
| 540777 540777 | ₹567.55 | ₹142.69 | -75% |
| Lupin Limited 500257 | ₹2,476 | ₹2,372 | -4% |
| 540719 540719 | ₹1,788 | ₹850.02 | -52% |
| 524804 524804 | ₹1,620 | ₹1,368 | -16% |
Explore undervalued stocks
Frequently asked questions
Is GRF-P undervalued?
What is the fair value of GRF-P?
What is the quality score of GRF-P?
What is the net profit margin of GRF-P?
Does GRF-P pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full GRF-P analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.